Development and characterization of a long-acting allosteric growth hormone receptor antagonist for acromegaly
Endocrinology · 03.08.2026 · 167 (9)
DOI: 10.1210/endocr/bqag090 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrinology, online erschienen am 07.08.2026. Verfasst von Katherine Kurylo und 15 weiteren Autor:innen. Beteiligte Einrichtung: Marea Therapeutics, South San Francisco, CA 94080, USA. Hauptthemen laut MEDLINE: Acromegaly, Receptors, Somatotropin, Human Growth Hormone, Antibodies, Monoclonal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Acromegaly is a rare disease caused by growth hormone (GH) hypersecretion from a pituitary adenoma. Pegvisomant is the only approved GH receptor antagonist (GHRA) and is administered via daily subcutaneous injections, which limits real-world effectiveness. Here, we report the discovery and characterization of MAR002, a novel, half-life extended monoclonal antibody GHRA. MAR002 was identified by immunizing transgenic mice with the extracellular domain of human and cynomolgus monkey GH receptor (GHR) and engineered with Fc modifications to limit effector function and extend serum half-life. MAR002 was benchmarked against pegvisomant in biophysical assays, cellular signaling inhibition studies, and a head-to-head pharmacokinetic/pharmacodynamic study in cynomolgus monkeys. MAR002 exhibited higher binding affinity to GHR and >100-fold more potent inhibition of GH-induced GHR signaling than pegvisomant (human half-maximal inhibitory concentration [IC50] 1.05 nM vs 122 nM). Epitope binning demonstrated simultaneous binding of MAR002 and GH to GHR, consistent with an allosteric, noncompetitive mechanism; notably, MAR002 inhibitory activity was maintained at supraphysiological GH concentrations, whereas pegvisomant activity was competitively reduced. In cynomolgus monkeys, a single 10 mg/kg intravenous dose of MAR002 sustained ≥50% IGF-1 suppression for 36 days compared with 15 days for an equimolar pegvisomant dose, with comparable maximal lowering (∼80%). These findings support clinical evaluation of MAR002 as a next-generation long-acting GHRA for acromegaly, with potential for reduced dosing frequency and more consistent suppression of the GH–IGF-1 axis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Marea Therapeutics, South San Francisco, CA 94080, USA.
- Mass General Brigham Innovation Fellows Program, Massachusetts General Hospital/Third Rock Ventures, Boston, MA 02114, USA.
- Alloy Therapeutics, Waltham, MA 02451, USA.
ORCID-Profile: Katherine Kurylo, Page R Bouchard, Mark N Milton, Peter F Moesta, Laura E Dichtel, Jack McGuire, Joshua Lehrer-Graiwer, Beryl B Cummings, Ethan J Weiss
Zitieren
APA
Kurylo, K., Bouchard, P. R., Milton, M. N., Moesta, P. F., Dichtel, L. E., Gromada, J., Ramanan, V., Vincent, T., Smith, M., Chang, C. S., McGuire, J., Shimkets, R., Joing, M. P., Lehrer-Graiwer, J., Cummings, B. B., & Weiss, E. J. (2026). Development and characterization of a long-acting allosteric growth hormone receptor antagonist for acromegaly. Endocrinology, 167(9). https://doi.org/10.1210/endocr/bqag090
Vancouver
Kurylo K, Bouchard PR, Milton MN, Moesta PF, Dichtel LE, Gromada J, et al. Development and characterization of a long-acting allosteric growth hormone receptor antagonist for acromegaly. Endocrinology. 2026;167(9). doi:10.1210/endocr/bqag090
BibTeX
@article{Kurylo2026,
author = {Kurylo, Katherine and Bouchard, Page R and Milton, Mark N and Moesta, Peter F and Dichtel, Laura E and Gromada, Jesper and Ramanan, Vyas and Vincent, Thomas and Smith, Melinda and Chang, Chew Shun and McGuire, Jack and Shimkets, Richard and Joing, Mark P and Lehrer-Graiwer, Joshua and Cummings, Beryl B and Weiss, Ethan J},
title = {Development and characterization of a long-acting allosteric growth hormone receptor antagonist for acromegaly},
journal = {Endocrinology},
year = {2026},
volume = {167},
number = {9},
doi = {10.1210/endocr/bqag090}
}
EUVIMED